title: Basal (18)F-FDG PET/CT as a predictive biomarker of tumor response for neoadjuvant therapy in breast cancer.
abstract: OBJECTIVE
  To explore the relation between tumor kinetic assessed by (18)F-FDG PET and final neoadjuvant chemotherapy (NC) response within a molecular phenotype perspective.
  
  
  METHODS
  Prospective study included 144 women with breast cancer. All patients underwent a dual-time point (18)F-FDG PET/CT previous to NC. The retention index (RI), between SUV-1 and SUV-2 was calculated. Molecular subtypes were re-grouped in low, intermediate and high-risk biological phenotypes. After NC, all residual primary tumor specimens were histopathologically classified in tumor regression grades (TRG) and response groups. The relation between SUV-1, SUV-2 and RI with the TRG and response groups was evaluated in all molecular subtypes and in accordance with the risk categories.
  
  
  RESULTS
  Responder's lesions showed significant greater SUVmax compared to non-responders. The RI value did not show any significant relation with response. Attending to molecular phenotypes, statistical differences were observed with greater SUV for responders having high-risk molecular subtypes.
  
  
  CONCLUSIONS
  Glycolytic tumor characteristics showed a significant correlation with NC response and dependence of risk phenotype.
authors.affiliation: Nuclear Medicine Department, University General Hospital, Ciudad Real, Spain. Electronic address: angarvice@yahoo.es.
authors.forename: A M
authors.initials: AM
authors.lastname: García Vicente
authors.affiliation: Nuclear Medicine Department, University General Hospital, Ciudad Real, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Soriano Castrejón
authors.affiliation: Department of Mathematics & IMACI-Institute of Applied Mathematics in Science and Engineering, University of Castilla-La Mancha, Ciudad Real, Spain.
authors.forename: R E
authors.initials: RE
authors.lastname: Pruneda-González
authors.affiliation: Department of Mathematics & IMACI-Institute of Applied Mathematics in Science and Engineering, University of Castilla-La Mancha, Ciudad Real, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Fernández Calvo
authors.affiliation: Oncology Department, Virgen de la Luz Hospital, Cuenca, Spain.
authors.forename: M M
authors.initials: MM
authors.lastname: Muñoz Sánchez
authors.affiliation: Oncology Department, Virgen de la Salud Hospital, Toledo, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Álvarez Cabellos
authors.affiliation: Oncology Department, La Mancha Centro Hospital, Alcázar de San Juan, Ciudad Real, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Espinosa Aunión
authors.affiliation: Pathology Department, University General Hospital, Ciudad Real, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Relea Calatayud
mesh_terms: D015415:Biomarkers; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D010641:Phenotype; D000072078:Positron Emission Tomography Computed Tomography; D011446:Prospective Studies
chemical_list: D015415:Biomarkers
keywords: (18)F-FDG PET/CT; (18)F-FDG PET/TC; Cinética tumoral; Cáncer de mama localmente avanzado; Fenotipos moleculares; Locally advanced breast cancer; Molecular phenotypes; Neoadjuvant chemotherapy response; Respuesta al tratamiento neoadyuvante; Tumor kinetics